Overview of Helicobacter pylori Infection in Indonesia: What Distinguishes It from Countries with High Gastric Cancer Incidence?

• Published in: Gut and liver Vol. 15; no. 5; pp. 653 - 665
• Main Authors: Muhammad Miftahussurur, Langgeng Agung Waskito, Kartika Afrida Fauzia, Isna Mahmudah, Dalla Doohan, I Ketut Adnyana, Ali Khomsan, Neneng Ratnasari, Yudith Annisa Ayu Rezkitha
• Format: Journal Article
• Language: Korean
• Published: 대한소화기기능성질환·운동학회 30.09.2021
• Subjects: Cancer; Gastric cancer risk; Helicobacter pylori; Indonesia
• ISSN: 1976-2283; 2005-1212

Helicobacter pylori infects more than half the human population. However, the prevalence in Indonesia is low, as is the prevalence of gastric cancer. Hence, it could be instructive to compare these prevalence rates and their determining factors with those of countries that have high gastric cancer incidence. Ethnicity and genetic characteristics of H. pylori are important determinants of the H. pylori infection rate in Indonesia. The infection rate is higher in Bataknese, Papuans and Buginese than in Javanese, the predominant ethnic group. Ethnicity is also an important determinant of the genetic characteristics of H. pylori. Analysis of CagA in the EPIYA segment showed that the predominant genotypes in Papuans, Bataknese and Buginese are ABB-, ABDand ABC-type CagA, respectively. Meanwhile, in the countries with high gastric cancer incidence, almost all strains had East Asian type CagA. An antibiotic susceptibility evaluation showed that the standard triple therapy can still be used with caution in several cities. There is a very high rate of resistance to second-line regimens such as levofloxacin and metronidazole. Recent studies have shown that furazolidone, rifabutin and sitafloxacin are potential alternative treatments for antibiotic-resistant H. pylori infection in Indonesia. Rather than focusing on early detection and eradication as in countries with high gastric cancer prevalence, countries with low gastric cancer prevalence should focus on screening the several groups that have a high risk of gastric cancer. (Gut Liver 2021;15:653-665)